<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109833</url>
  </required_header>
  <id_info>
    <org_study_id>368/2019BO1</org_study_id>
    <nct_id>NCT04109833</nct_id>
  </id_info>
  <brief_title>Early Antibiotic Therapy and Vaccination</brief_title>
  <official_title>Impact of Early Antibiotic Therapy on Vaccination Response in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal Sepsis is one of the most common causes of death in preterm infants. Therefore, up
      to 80% of very low birth weight infants receive antibiotic therapy in their first week of
      life. Antibiotic therapy is one of the most important influencing factors for the
      establishment of the intestinal microbiome, which in turn modulates neonatal immune
      development. In this pilot study, it will be investigated, if antibiotic therapy in the first
      week of life influences the vaccination response of preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to compare antibody titers against Hepatitis B, Polio, Pertussis,
      Haemophilus influenza B, Tetanus, Diphteria and Pneumococcus in very low birth weight infants
      (VLBWI) infants who received antibiotic therapy in their first week of life and who did not.
      In this pilot study, 20 VLBWI infants will be included (10 per group). Infants will be
      matched fo age and gender.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>vaccination reaction</measure>
    <time_frame>7 months</time_frame>
    <description>measurement of antibody titers for Hepatitis B, Polio, Pertussis, Haemophilus Influenza B, Tetanus, Diphteria and Pneumococcus 4 months after the first vaccination (at an age of 6 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome composition</measure>
    <time_frame>7 months</time_frame>
    <description>microbiome analyses of stool samples at age 14 days and corrected 4 months</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Vaccination Reaction</condition>
  <arm_group>
    <arm_group_label>no antibiotic therapy (ABT) in the first week of life</arm_group_label>
    <description>VLBWI with gestational age between 24+0 and 28+6 weeks of gestation without antibiotic treatment in the first week of life</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT in the first week of life</arm_group_label>
    <description>VLBWI with gestational age between 24+0 and 28+6 weeks of gestation with antibiotic treatment in the first week of life</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT</intervention_name>
    <description>any antibiotic therapy in the first week of life</description>
    <arm_group_label>ABT in the first week of life</arm_group_label>
    <other_name>any antibiotic therapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      stool samples for microbiome analyses
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        preterm infants with gestational age between 24+0 and 28+6 weeks of gestation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  born at University Hospital Tübingen

          -  at least one dose of antibiotics within the first week of life

        Exclusion Criteria:

          -  genetic disorders

          -  chronic infections

          -  hematological disorders

          -  immunoglobulins within the first 60 days of life

          -  immunological disorders

          -  infants from Hepatitis B positive mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natascha Köstlin-Gille, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Neonatology at University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natascha Köstlin-Gille, Dr. med.</last_name>
    <phone>0049-7071-2984743</phone>
    <email>natascha.koestlin@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Gille, Dr. med.</last_name>
    <phone>0049-7071-83972</phone>
    <email>christian.gille@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natascha Köstlin, Dr. med.</last_name>
      <phone>0049-7071-2984743</phone>
      <email>natascha.koestlin@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Natascha Köstlin-Gille</investigator_full_name>
    <investigator_title>Junior Research Group Leader</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

